{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T15:04:07Z","timestamp":1776524647698,"version":"3.51.2"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bigham and Women\u2019s Hospital"},{"name":"HORION"},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the risk of urolithiasis in gout patients initiating allopurinol, a xanthine oxidase inhibitor, vs benzbromarone, a uricosuric.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the 2011\u201320 Korea National Health Insurance Service database, we conducted a cohort study on gout patients initiating allopurinol vs benzbromarone as the first-line urate-lowering treatment. The primary outcome was a new onset urinary stone. The secondary outcome was a stone requiring intervention. We estimated hazard ratios (HRs) and 95% CIs using Cox proportional hazard models with a 5:1 ratio propensity-score matching on &amp;gt;80 variables. Subgroup analyses were done by age, sex, thiazide use and cardiovascular risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>61\u2009300 allopurinol initiators PS-matched on 12\u2009260 benzbromarone initiators were included (mean age 59\u2009years, 79% male). During a mean follow-up of 322\u2009days, 619 urolithiasis cases occurred with an incidence rate of 0.87 per 100 person-years in allopurinol and 1.39 in benzbromarone initiators, showing a HR of 0.64 (95% CI, 0.51\u20130.80). Approximately 44% of urinary stones required intervention with a HR of 0.61 (95% CI, 0.43\u20130.88). The lower risk associated with allopurinol compared with benzbromarone persisted across subgroups but was greater in the high than non-high cardiovascular risk subgroup (P for interaction\u2009=\u20090.02)<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This population-based cohort study found that allopurinol compared with benzbromarone was associated with a substantially lower risk of urolithiasis particularly in the presence of the high cardiovascular risk. This finding provides important safety information for clinicians\u2019 decision-making on urate-lowering treatments of different mechanisms of action.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae262","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T03:19:18Z","timestamp":1715397558000},"page":"2433-2441","source":"Crossref","is-referenced-by-count":8,"title":["Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-1159","authenticated-orcid":false,"given":"Eun Ha","family":"Kang","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital , Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital , Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Soo","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital , Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-1208","authenticated-orcid":false,"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Seoul National University College of Medicine, Seoul National University Hospital , Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-8611","authenticated-orcid":false,"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital , Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Curhan","sequence":"additional","affiliation":[{"name":"Channing Division of Network Medicine and Renal Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyon K","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School , Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"2024091608262516500_keae262-B1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41581-020-0320-7","article-title":"Determining the true burden of kidney stone disease","volume":"16","author":"Thongprayoon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2024091608262516500_keae262-B2","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.euf.2020.08.011","article-title":"Prevalence and trends in kidney stone among adults in the USA: analyses of National Health and Nutrition Examination Survey 2007-2018 data","volume":"7","author":"Abufaraj","year":"2021","journal-title":"Eur Urol Focus"},{"key":"2024091608262516500_keae262-B3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.eururo.2014.06.036","article-title":"Use of the National Health and Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030","volume":"66","author":"Antonelli","year":"2014","journal-title":"Eur Urol"},{"key":"2024091608262516500_keae262-B4","doi-asserted-by":"crossref","first-page":"e5287","DOI":"10.1136\/bmj.e5287","article-title":"Kidney stones and kidney function loss: a cohort study","volume":"345","author":"Alexander","year":"2012","journal-title":"BMJ"},{"key":"2024091608262516500_keae262-B5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2024091608262516500_keae262-B6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00240-020-01210-w","article-title":"Trends in the prevalence of kidney stones in the United States from 2007 to 2016","volume":"49","author":"Chewcharat","year":"2021","journal-title":"Urolithiasis"},{"key":"2024091608262516500_keae262-B7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","article-title":"Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2024091608262516500_keae262-B8","doi-asserted-by":"crossref","first-page":"j2376","DOI":"10.1136\/bmj.j2376","article-title":"Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies","volume":"357","author":"Li","year":"2017","journal-title":"BMJ"},{"key":"2024091608262516500_keae262-B9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.ajkd.2020.11.018","article-title":"Assessing the relationship between serum urate and urolithiasis using Mendelian randomization: an analysis of the UK Biobank","volume":"78","author":"Narang","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2024091608262516500_keae262-B10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.kint.2020.08.024","article-title":"A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout","volume":"99","author":"Bardin","year":"2021","journal-title":"Kidney Int"},{"key":"2024091608262516500_keae262-B11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42358-019-0106-4","article-title":"Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients","volume":"60","author":"Hoff","year":"2019","journal-title":"Adv Rheumatol"},{"key":"2024091608262516500_keae262-B12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12882-019-1441-8","article-title":"Evaluation of the chemical composition of nephrolithiasis using dual-energy CT in Southern Chinese gout patients","volume":"20","author":"Li","year":"2019","journal-title":"BMC Nephrol"},{"key":"2024091608262516500_keae262-B13","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.juro.2012.11.076","article-title":"Novel evaluation of nephrolithiasis as a complication of gout: a cross-sectional study using helical computerized tomography","volume":"189","author":"Shimizu","year":"2013","journal-title":"J Urol"},{"key":"2024091608262516500_keae262-B14","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1523-1755.2003.t01-2-00171.x","article-title":"The association between gout and nephrolithiasis in men: the Health Professionals' Follow-Up Study","volume":"64","author":"Kramer","year":"2003","journal-title":"Kidney Int"},{"key":"2024091608262516500_keae262-B15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1523-1755.2004.00386.x","article-title":"The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance","volume":"65","author":"Abate","year":"2004","journal-title":"Kidney Int"},{"key":"2024091608262516500_keae262-B16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1046\/j.1523-1755.2002.00508.x","article-title":"Pathophysiologic basis for normouricosuric uric acid nephrolithiasis","volume":"62","author":"Sakhaee","year":"2002","journal-title":"Kidney Int"},{"key":"2024091608262516500_keae262-B17","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.juro.2012.09.102","article-title":"Gout, stone composition and urinary stone risk: a matched case comparative study","volume":"189","author":"Marchini","year":"2013","journal-title":"J Urol"},{"key":"2024091608262516500_keae262-B18","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2024091608262516500_keae262-B19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"2024091608262516500_keae262-B20","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024091608262516500_keae262-B21","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1093\/eurheartj\/ehab619","article-title":"Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout","volume":"42","author":"Kang","year":"2021","journal-title":"Eur Heart J"},{"key":"2024091608262516500_keae262-B22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024091608262516500_keae262-B23","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/acr.20221","article-title":"Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout","volume":"62","author":"Perez-Ruiz","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024091608262516500_keae262-B24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s10157-018-1586-y","article-title":"Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study","volume":"22","author":"Yu","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2024091608262516500_keae262-B25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/imj.13173","article-title":"The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand","volume":"46","author":"Stamp","year":"2016","journal-title":"Intern Med J"},{"key":"2024091608262516500_keae262-B26","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40265-023-01944-y","article-title":"Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review","volume":"83","author":"Terkeltaub","year":"2023","journal-title":"Drugs"},{"key":"2024091608262516500_keae262-B27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.juro.2010.03.011","article-title":"Validity of administrative coding in identifying patients with upper urinary tract calculi","volume":"184","author":"Semins","year":"2010","journal-title":"J Urol"},{"key":"2024091608262516500_keae262-B28","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2024091608262516500_keae262-B29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2024091608262516500_keae262-B30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat-Simul C"},{"key":"2024091608262516500_keae262-B31","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-6646-9","volume-title":"Survival analysis: a self-learning text","author":"Kleinbaum","year":"2012","edition":"3rd ed"},{"key":"2024091608262516500_keae262-B32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"2024091608262516500_keae262-B33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4614-9575-8_7","volume-title":"Practical controversies in medical management of stone disease","author":"Sakhaee","year":"2014"},{"key":"2024091608262516500_keae262-B34","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJM198611273152204","article-title":"Randomized trial of allopurinol in the prevention of calcium oxalate calculi","volume":"315","author":"Ettinger","year":"1986","journal-title":"N Engl J Med"},{"key":"2024091608262516500_keae262-B35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.1968.03140370103030","article-title":"Allopurinol dissolution of renal uric acid calculi","volume":"205","author":"Wasko","year":"1968","journal-title":"JAMA"},{"key":"2024091608262516500_keae262-B36","first-page":"34","article-title":"Febuxostat promoted dissolution of radiolucent nephrolithiasis in patients with hyperuricemia","volume":"18","author":"Yunhua","year":"2020","journal-title":"Urol J"},{"key":"2024091608262516500_keae262-B37","first-page":"247","article-title":"Emerging uricosurics for gout","volume":"10","author":"Terkeltaub","year":"2017","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae262\/58167611\/keae262.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2433\/59135606\/keae262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2433\/59135606\/keae262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T08:27:07Z","timestamp":1726475227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/9\/2433\/7669121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,11]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae262","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,11]]}}}